Cargando…
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021
BACKGROUND: COVID-19 vaccines have been crucial in the pandemic response and understanding changes in vaccines effectiveness is essential to guide vaccine policies. Although the Delta variant is no longer dominant, understanding vaccine effectiveness properties will provide essential knowledge to co...
Autores principales: | Starrfelt, Jostein, Danielsen, Anders Skyrud, Buanes, Eirik Alnes, Juvet, Lene Kristine, Lyngstad, Trude Marie, Rø, Gunnar Øyvind Isaksson, Veneti, Lamprini, Watle, Sara Viksmoen, Meijerink, Hinta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436448/ https://www.ncbi.nlm.nih.gov/pubmed/36050718 http://dx.doi.org/10.1186/s12916-022-02480-4 |
Ejemplares similares
-
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
por: Seppälä, Elina, et al.
Publicado: (2021) -
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2023) -
High vaccine effectiveness against coronavirus disease 2019 (COVID-19) and severe disease among residents and staff of long-term care facilities in Norway, November 2020–June 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022) -
Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022
por: Langlete, Petter, et al.
Publicado: (2023) -
Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2022)